Non-Hodgkin´s lymphomas represent fifth most common malignant disease in the world. The incidence of lymphomas increased in 1970´s exponencially, now decreased to 1-2% increment per year.
At this moment 5-years overall survival is expected to be approximately 60%. Improvements of future analysis are possible via standardization of registries and cooperation.